CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 50 target
Drug / intervention
Ponatinib Hydrochloride +2 moredrug
Likely dose
Ponatinib Hydrochloride 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01746836
NCT01746836Phase 2RecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

M.D. Anderson Cancer Center·interventional·Posted Dec 11, 2012·Updated Mar 9, 2026

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Ponatinib Hydrochloride, and 1 other intervention for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 2 related conditions. Currently recruiting, targeting 50 participants across 1 site.

Detailed Summary

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by blocking a protein needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Recruiting
2013201420152016201720182019202020212022202320242025202620272028202920302031
First PostedDec 11, 2012
Enrollment StartJan 17, 2013
Primary CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 18.0 yearsPosted 13.6 years agoPrimary completion in 4.5 years

Interventions

Laboratory Biomarker Analysisother

Blood draws.

Ponatinib Hydrochloridedrug

Starting dose: 30 mg by mouth once a day.

Quality-of-Life Assessmentother

Surveys completed.